Ondine Biomedical Inc. NPV (CDI) (OBI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

9.25p
   
  • Change Today:
    -0.50p
  • 52 Week High: 19.00
  • 52 Week Low: 7.25
  • Currency: UK Pounds
  • Shares Issued: 226.75m
  • Volume: 39,379
  • Market Cap: £20.97m

Ondine Biomedical upbeat on photodisinfection study

By Josh White

Date: Tuesday 17 Jan 2023

LONDON (ShareCast) - (Sharecast News) - Ondine Biomedical said on Tuesday that a new study published in the journal Antibiotics found that antimicrobial photodisinfection therapy (aPDT) using its proprietary methylene blue-based photosensitiser in combination with a specific wavelength of light "effectively eradicated" pathogen biofilms commonly associated with periprosthetic joint infections (PJIs).
The AIM-traded firm said the results of the study suggested that photodisinfection could be used as an effective treatment method for PJIs, replacing current, more invasive approaches and potentially shortening antibiotic treatment.

It said that would both improve quality of life for patients, and also reduce morbidity, mortality, antibiotic resistance, and the high healthcare costs associated with treating such infections.

The company said the in vitro study, conducted by a research team from University Hospital Zurich, found that photodisinfection achieved 100% kill of the key pathogens in biofilms associated with PJIs.

They included the ESKAPE pathogens Staphylococcus aureus and Escherichia coli, and also Staphylococcus epidermidis, and Cutibacterium acnes, with no regrowth.

The photodisinfection treatment did not cause any relevant surface modification on any of the different prosthesis materials, suggesting that the therapy did not harm the material and would be safe to use in vivo.

"This is the first study to show that photodisinfection, also known as photodynamic therapy, could be an effective novel treatment for periprosthetic joint infections," said Dr Yvonne Achermann, lead author and senior physician for internal medicine and infectious diseases at Zollikerberg Hospital.

"This is particularly exciting as it provides a much-needed alternative to antibiotics as resistance in biofilm-forming bacteria continues to grow.

"We - the research team at University Hospital Zurich - are planning a clinical safety study to further explore the potential of photodisinfection to treat and even prevent PJIs."

At the close on Tuesday, shares in Ondine Biomedical were down 1.96% at 17.5p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OBI Market Data

Currency UK Pounds
Share Price 9.25p
Change Today -0.50p
% Change -5.13 %
52 Week High 19.00
52 Week Low 7.25
Volume 39,379
Shares Issued 226.75m
Market Cap £20.97m

OBI Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
55.16% below the market average55.16% below the market average55.16% below the market average55.16% below the market average55.16% below the market average
77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average77.78% below the sector average
Price Trend
56.69% below the market average56.69% below the market average56.69% below the market average56.69% below the market average56.69% below the market average
5.26% below the sector average5.26% below the sector average5.26% below the sector average5.26% below the sector average5.26% below the sector average
Income Not Available
Growth
45.85% below the market average45.85% below the market average45.85% below the market average45.85% below the market average45.85% below the market average
51.35% below the sector average51.35% below the sector average51.35% below the sector average51.35% below the sector average51.35% below the sector average

OBI Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
15:45 210 @ 9.50p
15:40 51 @ 9.00p
15:09 2,000 @ 9.37p
15:09 100 @ 9.50p
15:09 15 @ 9.50p

OBI Key Personnel

Chair Jean Charest
CEO Carolyn Cross

Top of Page